Why the study?
Does adriamycin by prolonged arterial infusion induce tumor regression in patients with advanced cancer?
Population
20 patients with different types of advanced cancer
Design
Case_series
Authors
Loading...
Should not change practice in advanced cancer; leaves open arterial adriamycin potential in head and neck tumors for controlled trials.
Does adriamycin by prolonged arterial infusion induce tumor regression in patients with advanced cancer?
Adriamycin by prolonged arterial infusion is a potent growth-inhibiting compound useful for inducing first remission in head and neck cancer, though associated with significant toxicity.
Pietro et al. (1970) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: